Clinical Trials Logo

Filter by:
NCT ID: NCT06380699 Completed - Clinical trials for Acute Ischemic Stroke

Study to Assess PK, Safety and Tolerability in Healthy Subjects

Start date: March 16, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses.

NCT ID: NCT06380660 Recruiting - Breast Cancer Clinical Trials

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Start date: March 22, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.

NCT ID: NCT06380309 Recruiting - Clinical trials for Advanced Malignant Solid Tumor of Digestive System

A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE

Start date: May 6, 2024
Phase: Early Phase 1
Study type: Interventional

Subjects were inoperable Chinese patients with histologically or cytologically confirmed advanced malignant solid tumors (mainly focusing on MSS type colorectal cancer) who had failed standard systemic therapy. In the first stage, each subject was given three doses on day 1, day 3 and day 5, and was divided into 4 dose groups, including 1 subject in the first dose group and 3-6 subjects in each of the last three dose groups. The second stage was the dose extension stage, with 2 dose groups, at least 10 subjects were enrolled in the selected group, and the administration method was the same as that of the first stage. There were about 20-60 cases in the two stages.

NCT ID: NCT06379867 Recruiting - Anesthesia Clinical Trials

A Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects

Start date: April 7, 2024
Phase: Phase 1
Study type: Interventional

Assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization for healthy subjects.

NCT ID: NCT06379568 Completed - Clinical trials for Fungal Infection Lungs

Risk of Aspergillus Infection in Patients With Chronic Lung Disease

Start date: July 1, 2022
Phase:
Study type: Observational

Large doses of systemic corticosteroids ,severe lung tissue damage and longer COPD diagnosis may increase the risk of IPA in patients with chronic structural lung disease. By comparing the risk factors of aspergillus colonization group and aspergillus infection group, the main risk factors of aspergillus pneumonia were determined.

NCT ID: NCT06379464 Recruiting - Depression Clinical Trials

Screening of New Markers of Gut Microbiota in Stroke and Depression: a Cross-sectional Study

Start date: September 1, 2023
Phase:
Study type: Observational

Objectives of Study: Through the cross-sectional study of stroke and depression, key biomarkers are targeted by screening disease-associated intestinal bacteria, metabolites and immune factors through multi-omics techniques.

NCT ID: NCT06379451 Not yet recruiting - Multiple Myeloma Clinical Trials

An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Start date: April 18, 2024
Phase: Early Phase 1
Study type: Interventional

Multiple myeloma (MM) is a malignant disease characterized by the abnormal proliferation of clonal plasma cells. However, multiple myeloma remains an incurable disease and requires the exploration of more effective treatment methods to improve the efficacy of relapsed refractory multiple myeloma and prolong survival time.Currently, clinical application of CAR-T is mostly based on autologous T cell preparation, while relapsed/refractory AML patients have undergone multiple chemotherapy treatments, resulting in impaired self-T cell function, which affects the efficacy and prognosis of CAR-T therapy. Therefore, it is necessary to find new alternative treatments. NK cells are important immune cells in the body and are an important component of innate immunity. Compared with CAR-T cell therapy, CAR-NK cells have unique advantages in adoptive cell therapy. NKG2D receptor is an activating receptor expressed on NK cells, which can recognize NKG2D ligands (NKG2DL) expressed on tumor cells, activating NK cell killing activity through NKG2D-NKG2DL interaction. Therefore, the investigators plan to treat relapsed multiple myeloma by infusing NKG2D-CAR-NK cells to evaluate its efficacy and safety.

NCT ID: NCT06379412 Recruiting - Colorectal Cancer Clinical Trials

A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Colorectal Cancer

Start date: July 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to explore the association of peptidoglycan fragments derived from gut microbiota with colorectal cancer (CRC). The main question it aims to answer is: Are peptidoglycan fragments from the gut microbiota associated with the progression of colorectal cancer? Participants will provide biological specimens (blood, feces, colon tissue obtained during surgery)

NCT ID: NCT06379399 Recruiting - Clinical trials for Colorectal Cancer Metastatic

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Start date: April 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-center, prospective, single-arm exploratory study aimed at evaluating the efficacy and safety of trifluridine/tipiracil in combination with cetuximab in the treatment of third-line and above RAS/BRAF wild-type metastatic colorectal cancer.

NCT ID: NCT06379386 Recruiting - Clinical trials for Aortic Valve Stenosis and Insufficiency

Long-term Prognosis and Valve Durability of TAVR

Start date: January 2016
Phase:
Study type: Observational

This registry aims to evaluate the long-term prognosis and valve durability of transcatheter aortic valve replacement (TAVR) in a real-world setting. Baseline characteristics, procedural data, and clinical outcomes will be collected in a prospective and observational manner.